title: Optical Coherence Tomography Angiography Study of Choroidal Neovascularization Early Response after Treatment.
abstract: OBJECTIVE
  Study the choroidal neovascularization (CNV) morphological evolution after treatment using optical coherence tomography angiography (OCTA).
  
  
  METHODS
  We used Optovue XR Avanti, with split-spectrum amplitude-decorrelation angiography algorithm.
  
  
  RESULTS
  OCT Angiography allows to recognize better the CNV type. In our series all our cases seem to follow a 45 to 60 days cycle, after intra vitreal injection. After each injection a pruning of smaller vessels is seen immediately (after 24 hours) that increases for 6 to 12 days when it reaches a maximum. It is followed by a reopening or new sprouting of the vessels 20 to 50 days later. The later cycles seem longer. Our results on early CNV evolution seem to confirm previous observations of CNV abnormalization and arterialization. Pruning the small peripheral branches seems to strengthen the trunk. In OCTA, closing terminal vessels (anti-VEGF effects) seems to cause an increased flow in trunk after the CNV reactivation.
authors.forename: Bruno
authors.initials: B
authors.lastname: Lumbroso
authors.forename: Marco
authors.initials: M
authors.lastname: Rispoli
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Savastano
authors.forename: Yali
authors.initials: Y
authors.lastname: Jia
authors.forename: Ou
authors.initials: O
authors.lastname: Tan
authors.forename: David
authors.initials: D
authors.lastname: Huang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000792:Angiography / Q000379:methods*; D002829:Choroid / Q000098:blood supply / Q000000981:diagnostic imaging; D020256:Choroidal Neovascularization / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000000981:diagnostic imaging / Q000188:drug therapy; D008297:Male; D012008:Recurrence; D041623:Tomography, Optical Coherence / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A